abbott 77003 has been researched along with valine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boucher, CA; Granneman, R; Ho, DD; Hsu, A; Jurriaans, S; Reedijk, M; Sereni, D; Tzeng, TB; van Bommel, T; Veyssier, P | 1 |
| Anderson, B; Erickson, JW; Gulnik, SV; Liu, B; Mitsuya, H; Suvorov, LI; Yu, B | 1 |
| Kempf, DJ; Krafft, GA; Li, S; Wang, GT; Wideburg, N | 1 |
| Baldwin, ET; Bhat, TN; Erickson, JW; Liu, B; Pattabiraman, N | 1 |
| Bilello, JA; Bilello, PA; Drusano, GL; Prichard, M; Robins, T | 1 |
| Erickson, J; Hoekzema, DT; Kageyama, S; Kempf, DJ; Kojima, E; Mitsuya, H; Murakawa, Y; Norbeck, DW; Shirasaka, T | 1 |
| Burt, SK; Chen, CM; Erickson, JW; Ho, DD; Kempf, DJ; Mo, H; Norbeck, D; Singh, MK; Toyoshima, T; Wideburg, NE | 1 |
| Erickson, JW; Everitt, L; Kaplan, AH; Kempf, DJ; Knigge, MF; Michael, SF; Norbeck, DW; Paul, DA; Swanstrom, R; Wehbie, RS | 1 |
| Bauer, G; Bilello, JA; Drusano, GL; Kort, JJ | 1 |
| Kaplan, AH; Kempf, DJ; Knigge, M; Norbeck, DW; Paul, DA; Swanstrom, R; Zack, JA | 1 |
| Bilello, JA; Bilello, PA; Drusano, GL; Dudley, MN; Kort, JJ; Leonard, J | 1 |
| Borman, AM; Clavel, F; Paulous, S | 1 |
| Alam, M; Bechtold, CM; Colonno, RJ; Gong, YF; Greytok, JA; Lin, PF; Robinson, BS; Rose, RE; Terry, BJ | 1 |
| Bilello, JA; Bilello, PA; Drusano, GL; Prichard, M | 1 |
| Bukovsky, A; Göttlinger, H | 1 |
| Burt, SK; Erickson, JW; Gulnik, SV; Ho, DD; Majer, P; Markowitz, M; Mo, H; Suvorov, LI | 1 |
| Baker, J; Böhnlein, E; Craik, CS; Escaich, S; Junker, U; McPhee, F; Plavec, I; Rose, JR | 1 |
| Ganem, D; Kedes, DH | 1 |
| Amado, RG; Chen, IS; Jamieson, BD; Kaplan, AH; Koka, PS; Withers-Ward, ES; Zack, JA | 1 |
| Bohacek, RS; McMartin, C | 1 |
| Hwang, MJ; Lee, CY; Tzou, WS; Yang, PK | 1 |
| Frecer, V; Miertus, S; Romeo, D; Tossi, A | 1 |
1 trial(s) available for abbott 77003 and valine
| Article | Year |
|---|---|
Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Methylurea Compounds; Middle Aged; Pyridines; RNA, Viral; Valine | 1995 |
21 other study(ies) available for abbott 77003 and valine
| Article | Year |
|---|---|
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
Topics: Amino Acid Sequence; Binding Sites; Carbamates; Cloning, Molecular; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Isoquinolines; Kinetics; Methylurea Compounds; Mutagenesis, Site-Directed; Oligopeptides; Point Mutation; Pyridines; Quinolines; Recombinant Proteins; Saquinavir; Structure-Activity Relationship; Thiazoles; Valine | 1995 |
Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.
Topics: Alcohols; Feasibility Studies; HIV Protease Inhibitors; Humans; Methylurea Compounds; Pyridines; Structure-Activity Relationship; Valine | 1995 |
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase.
Topics: Antiviral Agents; Drug Design; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Methylurea Compounds; Models, Molecular; Molecular Structure; Point Mutation; Protein Conformation; Pyridines; Thermodynamics; Valine | 1995 |
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; HIV Protease Inhibitors; HIV-1; Humans; Methylurea Compounds; Orosomucoid; Protein Binding; Pyridines; Valine; Zidovudine | 1995 |
A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro.
Topics: Antiviral Agents; Base Sequence; Cell Line; Gene Products, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Methylurea Compounds; Molecular Sequence Data; Pyridines; RNA, Viral; Valine; Virion; Zidovudine | 1994 |
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Microbial; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Methylurea Compounds; Models, Molecular; Molecular Sequence Data; Pyridines; Selection, Genetic; Sequence Homology, Amino Acid; Structure-Activity Relationship; Valine | 1994 |
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
Topics: Amino Acid Sequence; Base Sequence; DNA Primers; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Methylurea Compounds; Models, Molecular; Molecular Sequence Data; Point Mutation; Pyridines; Sequence Alignment; Sequence Homology, Amino Acid; Valine | 1994 |
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
Topics: Antiviral Agents; Blotting, Western; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; HIV Core Protein p24; HIV Protease Inhibitors; Humans; Immunoassay; Methylurea Compounds; Pyridines; Valine | 1993 |
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
Topics: Cells, Cultured; DNA, Viral; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Methylurea Compounds; Morphogenesis; Protease Inhibitors; Protein Processing, Post-Translational; Pyridines; Valine; Virion; Virus Replication | 1993 |
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
Topics: Antiviral Agents; Cell Line; DNA, Viral; Dose-Response Relationship, Drug; Flow Cytometry; HIV Core Protein p24; HIV Protease Inhibitors; HIV-1; Humans; Methylurea Compounds; Orosomucoid; Polymerase Chain Reaction; Pyridines; T-Lymphocytes; Valine; Virus Replication | 1995 |
Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Methylurea Compounds; Molecular Sequence Data; Mutation; Pyridines; Valine | 1996 |
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Topics: Amino Acid Sequence; Carbamates; Clone Cells; DNA Mutational Analysis; DNA, Recombinant; DNA, Viral; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ethanolamines; HeLa Cells; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Methylurea Compounds; Molecular Sequence Data; Point Mutation; Proviruses; Pyridines; Quinolines; Reassortant Viruses; Recombinant Fusion Proteins; Saquinavir; T-Lymphocytes; Urea; Valine | 1996 |
Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation.
Topics: Antiviral Agents; Cell Line; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Methylurea Compounds; Models, Biological; Monte Carlo Method; Pyridines; Valine; Zidovudine | 1996 |
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.
Topics: Animals; Base Sequence; Cricetinae; Endopeptidases; HIV Protease Inhibitors; HIV-1; Humans; Integrases; Methylurea Compounds; Molecular Sequence Data; Mutation; Pyridines; Valine; Virus Assembly; Virus Integration | 1996 |
Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
Topics: Amino Acid Sequence; Cell Line; Drug Design; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Methylurea Compounds; Molecular Sequence Data; Molecular Structure; Pyridines; Sequence Homology, Amino Acid; Structure-Activity Relationship; Valine | 1996 |
Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Drug Resistance, Microbial; Gene Expression; Genetic Variation; HIV Protease; HIV-1; Humans; Methylurea Compounds; Plasmids; Protease Inhibitors; Pyridines; Valine; Virus Replication | 1996 |
Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; DNA Probes; DNA, Viral; Foscarnet; Ganciclovir; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Methylurea Compounds; Nucleic Acid Hybridization; Organophosphonates; Organophosphorus Compounds; Phorbol Esters; Pyridines; Sarcoma, Kaposi; Tumor Cells, Cultured; Valine; Virus Replication | 1997 |
Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy.
Topics: Animals; Antigens, CD; Antigens, CD34; Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Flow Cytometry; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Depletion; Methylurea Compounds; Mice; Mice, SCID; Polymerase Chain Reaction; Proviruses; Pyridines; T-Lymphocytes; Thymus Gland; Transplantation, Heterologous; Valine; Zidovudine | 1997 |
QXP: powerful, rapid computer algorithms for structure-based drug design.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Binding Sites; Computer Simulation; Drug Design; HIV Protease; HIV Protease Inhibitors; Ligands; Methylurea Compounds; Models, Molecular; Molecular Structure; Monte Carlo Method; Proteins; Pyridines; Software; Thermodynamics; Valine; X-Ray Diffraction | 1997 |
Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations.
Topics: Chemical Phenomena; Chemistry, Physical; HIV Protease; HIV Protease Inhibitors; Methylurea Compounds; Oligopeptides; Pyridines; Sugar Alcohols; Thermodynamics; Valine | 1998 |
Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
Topics: Aspartic Acid Endopeptidases; Biological Availability; Crystallography; Drug Design; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; Methylurea Compounds; Models, Molecular; Molecular Structure; Mutation; Protein Binding; Pyridines; Solubility; Valine | 1998 |